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ABSTRACT: Neuromedin U (NMU) is a multifunctional neuropeptide which is characterized by a high conservation through all 
species. Herein, we describe the synthesis of a novel set of NMU-analogs based on the truncated NMU-8. Through combination of 
previously reported modifications, an elaborate structure-activity relationship study was performed aiming for the development of 
peptides with an increased selectivity towards NMU receptor 1 (NMUR1). Compound 7 possessed the highest NMUR1 selectivity 
(IC50 = 0.54 nM, selectivity ratio = 5313) together with an increased potency (EC50 = 3.7 nM), an 18% increase of the maximal 
effect at NMUR1 and a higher resistance against enzymatic degradation as compared to the native NMU-8. The development of a 
potent NMUR1 agonist with extended half-life could represent an attractive tool to further unveil the role of NMUR1 in NMU 
signaling. 
Neuromedin U (NMU) is a highly conserved neuropeptide 
which occurs in two main isoforms, a 23 to 25 amino acid 
long peptide, and in certain species a truncated version of 8 or 
9 amino acids is present and considered to be a degradation 
product from the larger peptide. The highest homology be-
tween variants in different species is found at the C-terminus 
of the NMU peptide with the C-terminal heptapeptide (-Phe-
Leu-Phe-Arg-Pro-Arg-Asn-NH2) being entirely conserved in 
mammalian species.1 NMU exerts its biological effects 
through two G protein-coupled receptors (GPCRs), more 
precisely neuromedin U receptor 1 (NMUR1) and NMUR2. 
These receptors have a complementary tissue distribution 
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since NMUR1 is most abundant in the periphery whereas 
NMUR2 is predominantly found in the central nervous sys-
tem.1,2 NMU is involved in various physiological processes 
including smooth muscle contraction, blood pressure control, 
regulation of the stress response, nociception, immune regula-
tion and suppression of feeding behavior.1 In the search for 
novel treatments in the field of obesity and diabetes, NMU is 
gaining interest since it is reported to exert anorexigenic ef-
fects and possess beneficial effects on glucose tolerance,3 
which resulted in extensive structure-activity relationship 
(SAR) studies and the development of different potent and 
long acting NMU-analogs.4-10 To date, several promising 
agonists for the NMURs are described, such as PEGylated 
NMU-258 and NMU-810,11 analogs, a NMU-human serum 
albumin conjugate,9 lipidated NMU-analogs,7,6 an alkylated 
NMU-analog,12 and all are reported to have potent and long-
lasting effects on food intake. Selective agonists towards 





4, resp.).  
Recently our group performed a SAR study, with the native 
NMU-8 sequence (H-Tyr1-Phe2-Leu3-Phe4-Arg5-Pro6-Arg7-
Asn8-NH2) as starting point and using human embryonic kid-
ney 293 (HEK293) cells expressing the NMURs for screening. 
Our study revealed that acetylation of the N-terminus results in 
peptides with a higher potency and plasma stability, as com-
pared to the non-acetylated analog. Secondly, replacement of 
the Tyr residue in position 1 by 7-hydroxy-L-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (7-OH-Tic), 2’-
naphtylalanine (2’Nal) or 2’,6’-dimethyltyrosine (Dmt) result-
ed in potent NMU-8 analogs. NMUR1 selectivity could be 
obtained by modification of the Phe4 residue whereas selec-
tivity towards NMUR2 was observed when Pro6 was modified. 
Finally, an increased resistance against proteolytic degradation 
was found for all molecules tested, as compared to NMU-8.13 
In this letter we report the synthesis and in vitro biological 
evaluation of a novel set of NMU-8 analogs, in which novel 
modifications were introduced, but also promising modifica-
tions of our previous findings were combined, with the aim to 
develop molecules with improved pharmacological profiles 
(Figure 1). The novel NMU-analogs were synthesized manual-
ly as reported before via conventional Fmoc-based solid phase 
peptide synthesis using Rink Amide AM resin as a solid sup-
port and 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium tetrafluoroborate (TBTU) / N,N-
diisoprpylethylamine (DIPEA) as coupling mixture (see Sup-
porting Information).13  N-substituted glycines (the so-called 
‘peptoid’ residues) were synthesized following the solid phase 
submonomer method.14 After complete deprotection and 
cleavage from the resin with trifluoroacetic acid (TFA) / tri-
ethylsilane (TES) / water (95/2.5/2.5 v/v/v), purification of the 
peptides was performed by preparative high-performance 
liquid chromatography (HPLC), using a water - acetonitrile 
gradient system containing 0.1 % TFA. All NMU-analogs had 
a purity greater than 95 % as assessed by HPLC analysis and 
their structure was confirmed by high resolution mass spec-
trometry (HRMS) (see Supporting Information, Table S1). 
Tritiated NMU-8, which was used for the binding studies, was 
obtained as described before (see Supporting Information for 
experimental details).13 Evaluation of the affinities and agonis-
tic activities of the NMU-analogs at the NMURs was per-
formed in the present study on HEK293 cells transiently ex-
pressing human (h)NMUR1 and hNMUR2 as reported 
before.13 Evaluation of the affinity of the novel NMU-analogs 
for the NMURs was performed with a competitive binding 
assay using [3H]-NMU-8 as radioligand. An inositol triphos-
phate (IP3) accumulation assay was carried out to study the 
functional activity of the NMU-analogs. All analogs were 
tested in at least 3 independent experiments using triplicates in 
a concentration range of 10-5 to 10-11 M. Table 1 shows the 
results for the novel NMU-analogs.  
Since previous SAR data revealed that N-terminal acetylation 
of NMU results in peptides with an increased potency and 
proteolytic stability, the current letter reports only acetylated 
NMU-analogs. Several studies state the C-terminal part of the 
sequence, more precisely -Pro-Arg-Asn-NH2, to be the core 
structure necessary for activation of the NMURs.4 Interesting-
ly, we successfully modified this critical region by modifica-
tion of the Pro6 residue and found that modification of this 
residue could lead to selectivity towards NMUR2.13 In the 
current study, this critical and conserved region was further 
explored. In a first step, Arg7 was replaced by the homologat-
ed β3homoArg (β3hArg) (to give compound 1, Ac-Tyr-Phe-
Leu-Phe-Arg-Pro-β3hArg-Asn-NH2). This NMU-analog dis-
played decreased affinity for both NMURs (IC50= 28.1 nM 
and 116.5 nM for NMUR1 and NMUR2, resp.). Additionally, 
it proved to be a full agonist at NMUR1 with a 4-fold reduc-
tion in potency in comparison with NMU-8. Compound 1 only 
partially activated NMUR2 with an EC50 value (i.e. 55.6 nM) 
in the range of the potency reported for NMU-8. When analog 
1 was compared with Ac-NMU-8, lower affinities and poten-
cies for both NMURs were found. By insertion of β-homo-
amino acids, the backbone is elongated by one carbon atom, in 
this case between the Arg7 and Asn8 residues. This shift might 
have caused an unfavorable projection of the side chains of 
these residues, 
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Table 1. In vitro affinity and activity of the NMU-analogs at hNMUR1 and hNMUR2. 
a The affinity (IC50 value) is calculated based on the competitive binding assay with [
3H]-NMU-8 as radioligand (Supporting Infor-
mation, Table S2, for Ki values). 
b The potency (EC50 value) is calculated based on the IP3 accumulation assay. 
c Emax is the percentage of 
the maximum response at 10-5 M compared with the NMU-8 response at the same concentration. d Receptor selectivity is expressed as the 
ratio of the IC50 value for NMUR2 over the IC50 value for NMUR1 of each analog. Sequences are shown below and modifications are 
marked in bold.  
eventually leading to a loss in binding to the NMURs. Alt-
hough it was reported that the C-terminal Asn8 is essential for 
NMUR activation, we modified this residue in two different 
manners: i) by the introduction of a methyl or benzyl group in 
the side chain amide of Asn, and ii) by modification of the C-
terminal amide. The addition of a methyl group in the side 
chain amide of Asn8 (to present compound 2, Ac-Tyr-Phe-
Leu-Phe-Arg-Pro-Arg-Asn(NMe)-NH2), caused a more than 
10-fold decreased affinity for the NMURs, when compared to 
NMU-8 and Ac-NMU-8, but a preserved potency as compared 
to the native NMU-8 peptide was found. Analog 3, in which a 
benzyl amide was present in the side chain of Asn8 (i.e, Ac-
Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn(NBzl)-NH2), possessed a 
NMU-8-like potency at NMUR1 in combination with a subna-
nomolar affinity. At NMUR2, this peptide was a partial ago-
nist (Emax = 65.8 %) with a decreased receptor affinity.  Next, 
we also modified the C-terminal amide. When a methyl or a 
benzyl group was inserted, to present compounds 4 (Ac-Tyr-
Phe-Leu-Phe-Arg-Pro-Arg-Asn-NHMe) and 5 (Ac-Tyr-Phe-
Leu-Phe-Arg-Pro-Arg-Asn-NHBzl), respectively, weak ago-
nists with a decreased affinity at both receptors were found. 
The loss in receptor binding and activation indicates that the 
C-terminal amidation is not only a natural protection mecha-
nism against carboxypeptidase driven degradation,15 but plays 
as well an important role in the NMUR binding and activation. 
Hence, we demonstrated that it is possible to modify the C-
terminal region of the NMU-8. The substitution of Arg7 by 
β3hArg resulted in a peptide which was still able to bind to the 
NMURs, although with a lower affinity as compared to NMU-
8, yet substantial receptor activation was found. Modification 
of the Asn residue also gave rise to full agonists for NMUR1 
which were able to activate the NMUR2 as well, though only 
partially. Our previous SAR study revealed that substitution of 
Phe4 by unnatural Phe- and Tyr-analogs served as a tool to 
obtain potent NMU-peptides with an increased NMUR1 selec-
tivity and improved plasma stability.13 Here, we report the 
synthesis of a NMU-analog in which Phe4  was replaced by 
(D,L)-2-aminotretralin-2-carboxylic acid (Atc), resulting in 
compound 6 (Ac-Tyr-Phe-Leu-Atc-Arg-Pro-Arg-Asn-NH2).
 
Due to peak overlay in the HPLC analysis, the resulting dia-
stereomers were inseparable and tested as a mixture. The 
introduction of Atc induced only a small selectivity shift to-
wards NMUR1, with a selectivity ratio (IC50 NMUR2 / IC50 




hNMUR2   Selectivity
d 
  Affinity  Potency  Affinity  Potency  IC50 NMUR2/ 
  IC50 (nM)a  EC50 (nM)b  Emax (%)c  IC50 (nM)  EC50 (nM)  Emax (%)  IC50 NMUR1 
 NMU-8 0.78 38.9 100.0 1.7 30.8 100.0 2 
 Ac-NMU-8 0.29 0.51 111.3 2.0 0.71 100.0 7 
1  28.1 155.7 113.2 116.5 55.6 81.4 4 
2  8.2 57.2 118.1 29.1 51.2 85.1 4 
3  0.75 10.9 93.8 18.8 28.6 65.8 25 
4  21.3 843.0 118.8 327.5 440.8 106.8 15 
5  37.0 1314 114.8 28.8 354.2 103.9 0.8 
6  8.8 28.5 106.9 40.4 3.8 91.4 5 
7  0.54 3.7 118.1 2869 1993 83.2 5313 
8  0.092 2.9 111.8 301.9 459.3 100.3 3282 
9  350.1 1028 64.0 598.9 2205 91.1 2 
10  3.0 18.9 127.7 465.5 925.2 97.2 155 
11  2.4 53.3 99.0 72.4 59.7 97.6 30 
1 Ac-Tyr-Phe-Leu-Phe-Arg-Pro-β3hArg-Asn-NH2 7 Ac-Dmt-Phe-Leu-Dmt-Arg-Pro-Arg-Asn-NH2 
2 Ac-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn(NMe)-NH2 8 Ac-7-OH-Tic-Phe-Leu-2’Nal-Arg-Pro-Arg-Asn-NH2 
3 Ac-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn(NBzl)-NH2 9 Ac-7-OH-Tic-Phe-Leu-N(4-OH-phenethyl)Gly-Arg-Pro-Arg-Asn-NH2 
4 Ac-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NHMe 10 Ac-7-OH-Tic-Phe-Leu-NMePhe-Arg-Pro-Arg-Asn-NH2 
5 Ac-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NHBzl 11 Ac-7-OH-Tic-Phe-Leu-Phe-Dap-Pro-Arg-Asn-NH2 
6 Ac-Tyr-Phe-Leu-Atc-Arg-Pro-Arg-Asn-NH2     
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NMURs as compared to NMU-8 with a slightly better 
NMUR2 potency. However, it did not reach the levels report-
ed for the Ac-NMU-8 potency. Neither selectivity towards 
NMUR1 nor the subnanomolar affinity for this receptor was 
observed for compound 6. A possible explanation can be the 
negative influence of the introduced Atc on the backbone 
folding, since α,α-dialkylated amino acids are known to in-
duce turn/helix conformations. Moreover, the aromatic moiety 
of the Atc residue could be positioned/stabilized differently, as 
compared to the one of 7-OH-Tic, 1’Nal, 2’Nal or Dmt. The 
Atc residue stabilizes the gauche (-) or trans with dihedral χ1 
angles of -60° and 180°, respectively, over the Cα-Cβ bond (in 
case of (S)-Atc).16,17 Next, we synthesized a series of peptides 
in which promising modifications were combined. With the 
aim to develop a NMUR1 selective agonist with increased 
potency and resistance against biodegradation, compound 7 
was synthesized in which both Tyr1 and Phe4 were replaced by 
Dmt (Ac-Dmt-Phe-Leu-Dmt-Arg-Pro-Arg-Asn-NH2). An 
increased selectivity towards NMUR1 was found for 7, which 
was of the same magnitude as reported for Ac-[Dmt4]-NMU-8 
(selectivity ratio of 5313 and 5158 for compound 7 and Ac-
[Dmt4]-NMU-8 respectively).13 Moreover, NMUR1 affinity 
and potency were in line with the ones found for the non-
selective Ac-[Dmt1]-NMU-8, more precisely a subnanomolar 
affinity in combination with an approximately 10-fold in-
creased activity at NMUR1, compared to NMU-8. Gratifying-
ly, the combination of the previously reported modifications to 
the NMU sequence (i.e. potency of Ac-[Dmt1]-NMU-8 and 
selectivity of Ac-[Dmt4]-NMU-8) culminated to the in vitro 
characteristics of the potent and selective analog 7. With the 
same goal in mind, Tyr in position 1 was replaced by the con-
formationally constrained 7-OH-Tic together with the intro-
duction of the bulky 2’Nal in position 4 to present compound 
8 (Ac-7-OH-Tic-Phe-Leu-2’Nal-Arg-Pro-Arg-Asn-NH2). 
Again, a cumulative effect of the modifications was found, 
resulting in a NMU-analog with a similar affinity and potency 
at NMUR1 as compared to Ac-[7-OH-Tic1]-NMU-8 (i.e. a 
subnanomolar affinity together with an increased potency 
compared to NMU-8), in combination with an elevated 
NMUR1 selectivity. An even 5-fold higher NMUR1 selectivi-
ty was observed compared to Ac-[2’Nal]-NMU-8 (selectivity 
ratio = 3282 and 610 for compound 8 and Ac-[2’Nal4]-NMU-
8, resp.),13 although the selectivity level of compound 7 was 
not exceeded. Our previous work revealed as well that the 
introduction of N-substituted glycines in position 4 of NMU-8 
resulted in weak and partial NMURs agonists. Nonetheless, 
the introduction of N(4-OH-phenethyl)Gly was able to extend 
plasma half-life up to 18 h (for NMU-8 only 4 min was 
found).13 With the aim to develop potent and proteolytically 
stable NMU-8 analogs, the use of a peptoid residue in position 
4 was combined with the replacement of Tyr1 by 7-OH-Tic, 
which was reported to give rise to potent NMURs agonists. 
Surprisingly compound 9 (Ac-7-OH-Tic-Phe-Leu-N(4-OH-
phenethyl)Gly-Arg-Pro-Arg-Asn-NH2) resulted in an even 
bigger loss in potency on both NMURs, as compared to Ac-
[N(4-OH-phenethyl)Gly4]-NMU-8 (EC50 = 216.6 nM and 
339.2 nM for NMUR1 and NMUR2 respectively).13 To verify 
whether the side chain is placed in an unfavorable position 
when peptoid residues are used or the backbone amide proton 
in that position is necessary for receptor interaction, an analog 
in which Phe4 was replaced by NMePhe, together with the 7-
OH-Tic substitution in position 1, was synthesized, to give 
compound 10 (Ac-7-OH-Tic-Phe-Leu-NMePhe-Arg-Pro-
Arg-Asn-NH2). A loss in affinity was observed at both 
NMURs, though more pronounced at NMUR2. Analog 10 was 
a weak agonist at NMUR2. At NMUR1, it exerted full and 
potent agonistic properties with a 27.7 % increase in the max-
imal effect at this receptor. These findings indicate that the 
side chain of the peptoid residues was in an unfavorable posi-
tion for receptor binding and activation rather than the need of 
the backbone amide proton for interaction with the NMURs. 
Of note, compound 10, encompassing the NMePhe residue in 
position 4, gave rise to the highest Emax values, tested to date 
(i.e. 127.7%), indicating that other N-alkylations might be 
worthwhile to investigate in search of selective hNMUR1 
agonists. Takayama et al described that selectivity towards 
NMUR2 could be obtained by substitution of Arg5 by α,β-
diaminopropionic acid (Dap).4 In the present study, the substi-
tution of Arg5 by Dap was combined with the introduction of 
7-OH-Tic in position 1, aiming for the development of a po-
tent NMUR2 receptor agonist with an elevated resistance 
against proteolytic degradation (Ac-7-OH-Tic-Phe-Leu-Phe-
Dap-Pro-Arg-Asn-NH2, compound 11). Surprisingly, analog 
11 possessed a 30-fold higher selectivity for NMUR1, alt-
hough it was equipotent at both NMURs with EC50 values of 
similar magnitude as compared to NMU-8.  
 
Figure 2. In vitro evaluation of NMU-analogs with increased 
NMUR1 selectivity. IP3 assay performed on HEK293 cells, tran-
siently expressing A) NMUR1 or B) NMUR2. Affinity for 
NMUR1 (C) or NMUR2 (D) was evaluated in a competitive 
binding assay with [3H]-NMU-8. For clarity, the selective com-
pounds 3 and 11 were not shown. Data are shown as mean ± SEM 
(n=3). 
Overall, this set of novel NMU-analogs contains several pep-
tides with an elevated selectivity towards NMUR1, whereas 
none of the compounds possessed NMUR2 selectivity. Figure 
2 gives an overview of the NMU-analogs with an improved 
selectivity profile. Especially compound 7 is a high-affinity, 
potent NMUR1 agonist (Figure 2A and 2C) with no signifi-
cant NMUR2 activation up to 10-6 M (relative inositol phos-
phate accumulation of 25.7 % at a concentration of 1 µM) due 
to a loss in receptor affinity (Figure 2B and 2D). 
An in vitro degradation study in human plasma was performed 
as described before13 (see Supporting Information) to investi-
gate the effect of the introduced modifications on the proteo-
lytic stability of a selection of the novel NMU-analogs. The 
Log[ligand] (M)
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percentage of intact peptide was measured in function of time 
via HPLC-UV analysis (Figure 3). To evaluate the degradation 
profile, samples were subsequently analyzed by LC-MS (Fig-
ure 4). NMU is characterized by a short half-life of less than 5 
min after subcutaneous injection.3 Moreover, the plasma half-
life of NMU-8 was found to be 4.3 ± 0.2 min, with the neuro-
peptide being rapidly cleaved at its N-terminus. N-terminal 
acetylation of NMU-8 was able to increase the resistance 
against proteolytic degradation, resulting in a 25-fold longer 
half-life. The cleavage site after Tyr1 was protected by acetyla-
tion of the N-terminus and degradation of Ac-NMU-8 oc-
curred by cleavage between Phe2-Leu3.13  
Figure 3. Relative recovery over time of the NMU-analogs in 
human plasma at 37°C and calculated half-lifes. Experiments 
were performed in triplicate and data are presented as mean ± SD. 
As can intuitively be expected, modification of the Arg7 
(β3hArg in 1) or Asn8 (Asn(NMe) in 2, Asn(NBzl) in 3) resi-
due, together with N-terminal acetylation, did not stabilize the 
Phe2-Leu3 cleavage site, and calculated half-lifes of 156.4 ± 
10.5 min and 166.8 ± 5.4 min were found for compounds 2 
and 3 respectively. Although replacement of Arg7 by β3hArg 
did not alter the major cleavage site of the peptide, an extraor-
dinary resistance against biodegradation was observed result-
ing in a half-life of 1170.5 ± 128.4 min (or 19.5 ± 2.1 h) in 
human plasma for analog 1. We previously reported that the 
major cleavage site of the NMU-analogs was shifted to the 
middle of the sequence, between Phe4 and Arg5, when Tyr1 
was substituted by 7-OH-Tic or 2’Nal, or upon replacement of 
Phe4 by Dmt.13 When both Tyr1 and Phe4 were substituted, as 
for compounds, 7 (Ac-[Dmt1,Dmt4]-NMU-8), 8 (Ac-[7-OH-
Tic1,2’Nal4]-NMU-8) and 10 (Ac-[7-OH-Tic1,Dap4]-NMU-8),  
two major cleavage sites were found more precisely, in the 
middle of the sequence and between Arg7-Asn8 (Figure 4). For 
NMU-analogs 7 and 8, the major degradation site was found 
to be in the middle of the NMU-sequence, between the modi-
fied Phe4 residue and Arg5, resulting in plasma half-lifes of 
201.5 ± 6.3 min and 142.3 ± 1.3 min for 7 and 8 respectively. 
In a smaller extent, the peptides were cleaved between Arg7-
Asn8. These degradation profiles indicate that unnatural amino 
acids such as Dmt and 2’Nal are able to suppress, but not 
eliminate, hydrolysis of the adjacent amide bonds. When the 
backbone amide of the Phe residue in position 4 was modified, 
as in the case of compound 10 where Phe4 was replaced by 
NMePhe, the priority of the biodegradation sites switched to 
Arg7-Asn8 as the major cleavage site (see Supporting Infor-
mation, Table S4 and Figure S5). The scissile Phe4-Arg5 amide 
bond was protected by the introduction of a methyl group on 
the backbone amide and was only cleaved in a minor extent, 
resulting in a prolonged half-life of 1804.2 ± 77.5 min (or 30.1 
± 1.3 h). Again, this observation indicates that N-alkylation of 
the amide bond between Phe4 and Arg5 seems a promising 
avenue towards extremely stable hNMUR1 agonists.  
 
Figure 4. Schematic representation of the biodegradation profiles 
of the novel NMU-analogs. Colored amino acid positions (AA) 
indicate where modifications are introduced (cfr. Figure 1). The 
major cleavage sites are indicated with dotted lines. 
In conclusion, the present study proves that modifications in 
the C-terminal region, previously reported as critical segment, 
of the NMU-8 sequence are tolerated.  Moreover, the substitu-
tion of the Arg7 by β3hArg increased the resistance against 
proteolytic degradation resulting in a half-life of more than 19 
h in human plasma. Importantly, we synthesized a series of 
NMU-analogs with an increased selectivity for NMUR1. The 
novel NMU-derivative 7 possesses subnanomolar affinity for 
the receptor and a 10-fold increased potency as compared to 
NMU-8, together with an 18 % higher Emax. No significant 
NMUR2 receptor activation was found up to 10-6 M. Moreo-
ver, a more than 50-fold extension of the plasma half-life was 
observed for compound 7. When modifications were intro-
duced in the backbone, as for analog 10, a plasma half-life up 
to 30 h was found. In general, stabilization of the Phe4-Arg5 
bond is necessary for obtaining NMU-8 analogs with pro-
longed plasma stability. We are convinced that potent and 
proteolytical stable NMUR1 agonists, such as the ones report-
ed in this report, could serve as useful tools for further eluci-
dating to role of this receptor in NMU signaling, which seems 
to be involved in feeding behavior and glucose tolerance.3, 18 
Moreover, NMUR1 is recently gaining a lot of attention since 
it seems to play a role in type 2 lymphoid driven inflammation 
and allergic lung inflammation.19-21   
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